# Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

> **NCT00608972** · PHASE2 · COMPLETED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 31 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Doxil
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00608972
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05-16
- **Primary completion:** 2015-07-12
- **Final completion:** 2015-09-25
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00608972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00608972, "Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00608972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*